Abstract
Dysregulation of the mammalian target of rapamycin (mTOR) pathway has been observed in many human tumors and has been found to be implicated in the promotion of cancer cell growth and survival. Hence, the mTOR pathway is considered an important target of anticancer therapy. This paper focuses on the role of mTOR inhibition and on the recent developments of the mTOR inhibitor everolimus (RAD001) in this field.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
